Intestinal Microbiota and Arterial Stiffness

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

181 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-04-03

Study Completion Date

2020-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an observational case-control study which objective is to analyse differences in intestinal microbiota between patients with and without arterial stiffness, measured by pulse wave velocity. It will take place in two different research units located in Portugal and Spain.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Lifestyles, Arterial Aging and Intestinal Microbiota (MIVAS III Study)

NCT04924907

Arterial Stiffness Dysbiosis

COMPLETED

Is Our Microbiome a Predictor of Cardiac Risk

NCT02013284

Coronary Artery Disease

ENROLLING_BY_INVITATION

Metabolomics, Genomics and Nutrition for Cardiovascular Disease Precision Medicine

NCT05706519

Ischemic Heart Disease Coronary Heart Disease

UNKNOWN

Age-associated Arterial Dysfunction, Western Diet, and Aerobic Exercise: Role of the Gut Microbiome

NCT03334201

Aging

UNKNOWN NA

Etiology and Prevalence of Peripheral Arterial Disease

NCT00005142

Cardiovascular Diseases Peripheral Vascular Diseases Arterial Occlusive Diseases

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Aim: analyse differences in intestinal microbiota between patients with and without arterial stiffness, measured by pulse wave velocity.

Design and setting: An observational case-control study. Study population: The investigators will select 324 subjects, between 30 to 75 years-old, from a database that combine data from four different studies: Triple A, Early vascular Aging (EVA) and Improving interMediAte Risk management (MARK) that took place in the Research Unit of La Alamedilla Primary Care Center, and Guimarães/ Vizela Study promoted by the Life and Health Sciences Research Institute in Minho University.

Measurements: 162 Cases will be defined by a Carotid-femoral Pulse Wave Velocity (cf-PWV)\>10 mm/s determined using the SphygmoCor System. 162 controls will be selected by the propensity score. The composition of the gut microbiome in faecal samples will be determined by ribosomal ribonucleic acid (16S rRNA) gene sequencing. Other measurements: demographic data, lifestyle assessment (physical activity, adherence to the Mediterranean diet, alcohol and tobacco consumption). Anthropometric Variables: Weight, body composition by bioimpedance, size, body mass index (BMI), waist and hip perimeter, peripheral and central arterial pressure. Analysis of structure and vascular function and organ lesions target: pulse wave velocity, cardio-ankle vascular index and ankle-brachial index; Intimal median carotid thickness, central and peripheral rate of increase, renal and cardiac organic lesion. Blood analysis: short chain fatty acids, total bile acids, ursodeoxycholic acid

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arterial Stiffness Dysbiosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PWV>10

Patients with PWV \> 10 (SSphygmoCor) in two different measurements

No interventions assigned to this group

PWV<10

Patients with PWV \< 10 (SphygmoCor) in two different measurements

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

* Participants who are in terminal condition,
* Participants with a history of cardiovascular disease (ischaemic heart disease or stroke, peripheral arterial disease or Heart Failure),
* People with diabetes,
* diagnosed renal failure in terminal stages (glomerular filtration rate below 30%),
* chronic inflammatory disease or acute inflammatory process in the past 3 months.
* Patients treated with oestrogens, testosterone or growth hormone,

Minimum Eligible Age

40 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes